Login
Home / JCRRF : OTC
Follow Compare
AI Analysis Fundamentals Valuation Video Analysis News Similar
Quarterly Quarterly (TTM) Annually

AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

JCR Pharmaceuticals Co., Ltd.

$3.33 -$1.42 (-29.89%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$3.33
Day Range
$3.32$3.33
Year Range
$3.15$4.75
Market Cap
406.32M
AVG Volume
669
Trailing/Forward PE
77.08/1.05
PEG ratio
437.39
Dividend Yield
3.86%
Next Earnings Date
2026-10-28
Primary Exchange
Other OTCUS
Revenue (JPY)
05B10B15B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Net Income (JPY)
-6B-4B-2B02B4B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Operating Income (JPY)
-7.5B-5B-2.5B02.5B5B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
EBITDA (JPY)
-7.5B-5B-2.5B02.5B5B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Cash Flows (JPY)
00.250.50.75124 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
EPS (JPY)
-40-2002024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Expenses (JPY)
010B20B30BR&DSG&A24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Cash & Debt (JPY)
020B40B60BCashLong Term DebtShort Term Debt24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Debt ratios
-100010020024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Margins
0%25%50%75%100%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Return on Capital
-200%0%200%400%600%800%24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Shares Outstanding
050M100M150M24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Dividends (JPY)
00.020.040.060.08Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Sep 26Mar 27
Book Value Per Share (JPY)
020040060024 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
Total Assets (JPY)
050B100B150B24 Q425 Q125 Q225 Q325 Q426 Q126 Q226 Q326 Q427 Q1
PE Ratio
1020304050med 28.46Mar 23Jun 23Oct 23May 24Aug 24Nov 24Sep 26
Free Cash Flow Yield
0%2%4%6%med 0%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
Price to Sales
1.522.533.5med 2.44Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
EV/EBITDA
0200400600800med 17.53Mar 24Jul 24Oct 24Jan 25May 25May 26Sep 26
Price/Operating Cashflow
0100200300400med 41.66Mar 23Jul 23Oct 23May 24Aug 24Dec 24Mar 25
Price to Book
0100200300med 1.58Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
JCR Pharmaceuticals Co., Ltd.
JCRRF
Stockpicker

Video analysis: JCRRF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: JCRRF

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

businesswire.com · 11 Sep 2026

MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

TOKYO & HYOGO, Japan--(BUSINESS WIRE)--JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

businesswire.com · 21 Jul 2026

JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that IZCARGO, an enzyme replacement therapy indicated for Hunter syndrome, received marketing authorization in the United Arab Emirates.
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

businesswire.com · 17 Jun 2026

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer's disease (AD), enabled by JCR's proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo®

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.